Chile vs Tonga: Pneumococcal conjugate second or third-dose vaccines (PCVc) immunizati
Chile
94.0%
in 2025
Tonga
94.0%
in 2025
Chile rank
46th
Tonga rank
46th
Pneumococcal conjugate second or third-dose vaccines (PCVc) immunizati over time
- Chile
- Tonga
How they compare
Chile currently reports 94.0% against 94.0% in Tonga, a difference of 0.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was Tonga ahead.
Chile ranks 46th and Tonga ranks 46th of 194 countries.
Chile has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Chile | Tonga | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 77.1% | 0.0% | 77.1% | Chile |
| 2020s | 92.3% | 71.0% | 21.3% | Chile |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc) immunizati, Chile or Tonga?
- Chile, at 94.0% against 94.0% in Tonga as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) immunizati between Chile and Tonga?
- 0.0%, with Chile ahead.
- How many years of comparable data are there for Chile and Tonga?
- 18 years are reported by both, from 2008 to 2025.
- How do Chile and Tonga rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc) immunizati?
- Chile ranks 46th and Tonga ranks 46th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.